Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )
1 Jun 2019

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC

Dr Edward B. Garon - UCLA, Los Angeles, USA
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019

Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients

Dr Edward B. Garon - UCLA, Los Angeles, USA
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019

Comment: The success of immunotherapy means we have to change our mindset as we treat patients

Dr David Graham and Dr Edward B. Garon
Comment: The success of immunotherapy means we have to change our mindset as we treat patients ( Dr David Graham and Dr Edward B. Garon )
1 Jun 2019

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain )
1 Jun 2019

Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy

Dr Richard Schilsky and Dr Josep Tabernero
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy ( Dr Richard Schilsky and Dr Josep Tabernero )
1 Jun 2019

Ovarian cancer: Current treatments and latest advances

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Ovarian cancer: Current treatments and latest advances ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 May 2019

Latest in ovarian cancer treatment

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Latest in ovarian cancer treatment ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 May 2019

Novel adoptive cell therapies for acute lymphoblastic leukaemia

Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany
Novel adoptive cell therapies for acute lymphoblastic leukaemia ( Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany )
24 May 2019

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse

Prof David Marks - University Hospital Bristol, Bristol, UK
Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse ( Prof David Marks - University Hospital Bristol, Bristol, UK )
24 May 2019

Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia

Prof Hervé Dombret, University Paris Diderot, Paris, France
Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Prof Hervé Dombret, University Paris Diderot, Paris, France )
24 May 2019

Pharmacology update from ONS 2019

Teresa Knoop - Vanderbilt Ingram Cancer Center, Brentwood, USA
Pharmacology update from ONS 2019 ( Teresa Knoop - Vanderbilt Ingram Cancer Center, Brentwood, USA )
8 May 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation